Advertisement
GSK vs LLY
Which Stock Would AI Choose? GSK plc (GSK) vs. Eli Lilly and Company (LLY) Stock Comparison
Key Takeaways
- GSK is gaining momentum on specialty medicines, oncology, and a landmark U.S. hepatitis B approval, while LLY remains a high-growth leader in obesity and diabetes treatments.
- LLY has delivered far stronger recent revenue growth and became the first pharmaceutical company to reach a $1 trillion market capitalization, but it trades at a much higher valuation.
- GSK offers a value-oriented profile with a lower price-to-earnings (P/E) ratio and a multi-year efficiency program, though its growth outlook is more moderate.
- Investor sentiment toward GSK has improved in recent weeks on pipeline and cost-cutting news, while LLY sentiment reflects exceptional but more fully priced growth expectations.
- The two companies represent contrasting risk-reward profiles: diversification and value versus concentration and high growth.
- For further context on each name, explore GSK Major News and GSK Today's Price Move, as well as LLY Major News and LLY Today's Price Move.
- To see how automated strategies are positioning across these and other tickers, explore Trending AI Robots.
Introduction
This stock comparison examines two prominent pharmaceutical companies occupying very different positions in the market: GSK, the UK-based diversified drugmaker focused on specialty medicines, vaccines, and HIV (human immunodeficiency virus) treatments, and LLY, the U.S.-based giant that has redefined the obesity and diabetes market through its GLP-1 (glucagon-like peptide-1) medicines. Growth-oriented investors weighing relative performance and market positioning may be drawn to LLY's momentum, while value-conscious investors may find GSK's lower valuation and improving pipeline more appealing. Understanding how each stock's recent price behavior, catalysts, and risk factors compare can help traders and longer-term investors alike evaluate where these names stand today.
GSK Overview and Recent Performance
GSK (GSK plc, formerly GlaxoSmithKline) has shifted toward higher-growth specialty medicines in oncology, HIV, and respiratory and immunology. In recent market activity, the stock has drawn support from a quarterly report that beat expectations on sales and core earnings, led by specialty medicines and a rebound in vaccines, particularly meningitis. Management confirmed full-year guidance and indicated revenue growth would likely land toward the upper end of its range.
Sentiment has been further boosted by a U.S. Food and Drug Administration (FDA) approval of its chronic hepatitis B treatment, described by Reuters as potentially allowing some patients to stop long-term therapy, alongside an accelerated approval for Jemperli in a form of rectal cancer. A newly announced multi-year efficiency program and continued acquisition-led expansion in oncology—including a licensing deal with HUTCHMED—have reinforced the narrative of an improving research and development (R&D) pipeline. Analysts remain split, with Berenberg issuing a Buy rating while others, such as JPMorgan, maintain an Underweight stance, reflecting lingering concerns over patent expiries in its general medicines portfolio.
LLY Overview and Recent Performance
LLY (Eli Lilly and Company) has emerged as one of the fastest-growing large pharmaceutical companies, driven by surging demand for its incretin medicines—Mounjaro for type 2 diabetes and Zepbound for obesity. The company reported 54% year-over-year revenue growth in a recent quarter and roughly $65 billion in full-year revenue, becoming the first drugmaker to reach a $1 trillion market capitalization. This performance has been fueled by volume growth rather than price increases.
Recent catalysts include a landmark agreement with the U.S. government to expand Medicare and Medicaid access to its obesity medicines, expected to significantly widen its addressable patient base. Lilly has also submitted its oral GLP-1 candidate, orforglipron, for regulatory review and is advancing later-stage medicines such as retatrutide and eloralintide, while investing tens of billions of dollars in manufacturing capacity. This growth, however, is reflected in a premium valuation—its P/E ratio has hovered far above the broader pharmaceutical sector—making the stock sensitive to any slowdown in obesity demand or pipeline setbacks.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots drawn from hundreds available on the platform, which collectively trade thousands of different tickers. Only the bots best suited to current market conditions earn a place in this section. These bots differ widely in trading style, strategy, timeframe, performance history, and the specific tickers they trade, allowing users to compare statistics such as win rates, trade frequency, and drawdown before choosing a match. Because each bot applies its own analytical approach to momentum, trend, and volatility, the section serves as a practical entry point for traders evaluating automated strategies across names like GSK and LLY. Exploring Trending AI Robots can help you identify strategies aligned with the current market environment.
Head-to-Head Comparison
The contrast between these two companies is stark across several dimensions. In business model, GSK is a diversified specialist spanning infectious disease, vaccines, and oncology, whereas LLY is increasingly concentrated around a high-growth metabolic franchise. In growth drivers, LLY's GLP-1 portfolio generates exceptional top-line expansion, while GSK's growth is more measured and relies on specialty medicine launches and acquisitions.
On recent momentum, both stocks have advanced, but for different reasons: LLY on durable demand and government coverage, GSK on improving pipeline news and efficiency initiatives. The key trade-off lies in valuation and risk. GSK trades at a relatively modest forward P/E and a dividend-supported profile, but faces patent cliffs and generic erosion in general medicines. LLY commands a premium multiple that prices in sustained dominance, leaving less margin for error if competition intensifies or obesity demand moderates. In sector exposure and sentiment, LLY is viewed as a growth platform comparable to technology leaders, while GSK is positioned as a turnaround story shedding its legacy underperformance.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor LLY on trend consistency and momentum, given its sustained revenue acceleration, dominant market positioning, and supportive catalysts such as expanded Medicare coverage and the orforglipron submission. Its stronger relative performance and clearer growth trajectory align with trend-following signals. However, GSK may hold an advantage on valuation and stability-oriented criteria, with a lower entry multiple and improving, lower-volatility catalysts. In probabilistic terms, an AI model weighting momentum and catalysts would lean toward LLY, while one weighting value and risk reduction might favor GSK—making the choice highly dependent on the specific strategy and timeframe applied.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Buy and LLY is a Hold.
Momentum Indicator for GSK turns positive, indicating new upward trend
GSK saw its Momentum Indicator move above the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned positive. In 49 of the 77 cases, the stock moved higher in the following days. The odds of a move higher are at 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GSK's RSI Oscillator exited the oversold zone, 14 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on October 15, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 28 of 45 cases over the following month. The odds of a continued upward trend are 62%.
GSK moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 55%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 29 of 58 cases where GSK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GSK entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 39 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.622) is normal, around the industry mean (-1.376). P/E Ratio (20.646) is within average values for comparable stocks, (21.842). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.036) settles around the average of (0.039) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
LLY in upward trend: 10-day moving average broke above 50-day moving average on October 15, 2026
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 51 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for LLY just turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 233 of 297 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (37.296) is slightly higher than the industry average of (-1.376). P/E Ratio (47.489) is within average values for comparable stocks, (21.842). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.039) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
GSK | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 46 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 39 | 5 | |
SMR RATING 1..100 | 34 | 14 | |
PRICE GROWTH RATING 1..100 | 51 | 4 | |
P/E GROWTH RATING 1..100 | 9 | 26 | |
SEASONALITY SCORE 1..100 | 65 | 25 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (80) in the Pharmaceuticals Major industry is in the same range as LLY (88). This means that GSK’s stock grew similarly to LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (39). This means that LLY’s stock grew somewhat faster than GSK’s over the last 12 months.
LLY's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as GSK (34). This means that LLY’s stock grew similarly to GSK’s over the last 12 months.
LLY's Price Growth Rating (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (51). This means that LLY’s stock grew somewhat faster than GSK’s over the last 12 months.
GSK's P/E Growth Rating (9) in the Pharmaceuticals Major industry is in the same range as LLY (26). This means that GSK’s stock grew similarly to LLY’s over the last 12 months.
| GSK | LLY | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 61% | 3 days ago 56% |
| Stochastic ODDS (%) | 3 days ago 50% | 3 days ago 52% |
| Momentum ODDS (%) | 3 days ago 64% | 3 days ago 62% |
| MACD ODDS (%) | 3 days ago 62% | 3 days ago 82% |
| TrendWeek ODDS (%) | 3 days ago 55% | 3 days ago 70% |
| TrendMonth ODDS (%) | 3 days ago 59% | 3 days ago 69% |
| Advances ODDS (%) | 17 days ago 63% | 3 days ago 70% |
| Declines ODDS (%) | 4 days ago 56% | about 1 month ago 55% |
| BollingerBands ODDS (%) | 3 days ago 47% | 3 days ago 47% |
| Aroon ODDS (%) | 3 days ago 44% | 3 days ago 78% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 1 FA rating(s) are green while LLY’s FA Score has 4 green FA rating(s).
- GSK’s FA Score: 1 green, 4 red.
- LLY’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 6 TA indicator(s) are bullish while LLY’s TA Score has 6 bullish TA indicator(s).
- GSK’s TA Score: 6 bullish, 4 bearish.
- LLY’s TA Score: 6 bullish, 4 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а -2.44% price change this week, while LLY (@Pharmaceuticals: Major) price change was +11.31% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.16%. For the same industry, the average monthly price growth was -2.39%, and the average quarterly price growth was +4.91%.
Reported Earning Dates
GSK is expected to report earnings on Feb 03, 2027.
LLY is expected to report earnings on Feb 10, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+0.16% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with JNJ. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then JNJ could also see price increases.